NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 02:20PM ET
3.01
Dollar change
+0.03
Percentage change
1.01
%
Index- P/E- EPS (ttm)-3.33 Insider Own1.53% Shs Outstand139.11M Perf Week-4.91%
Market Cap418.72M Forward P/E- EPS next Y-0.94 Insider Trans0.00% Shs Float136.98M Perf Month-16.85%
Enterprise Value374.91M PEG- EPS next Q-0.61 Inst Own2.44% Short Float0.02% Perf Quarter2.38%
Income-199.33M P/S42.04 EPS this Y74.27% Inst Trans146.93% Short Ratio1.40 Perf Half Y36.81%
Sales9.96M P/B- EPS next Y-9.41% ROA-200.13% Short Interest0.03M Perf YTD40.65%
Book/sh-1.16 P/C4.19 EPS next 5Y36.99% ROE- 52W High4.05 -25.68% Perf Year0.67%
Cash/sh0.72 P/FCF- EPS past 3/5Y-30.56% -18.31% ROIC- 52W Low1.53 96.73% Perf 3Y-61.27%
Dividend Est.- EV/EBITDA- Sales past 3/5Y26.14% 4.90% Gross Margin61.02% Volatility6.81% 7.13% Perf 5Y-
Dividend TTM- EV/Sales37.64 EPS Y/Y TTM-26.67% Oper. Margin-1080.58% ATR (14)0.25 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.92 Sales Y/Y TTM-47.32% Profit Margin-2001.94% RSI (14)40.99 Recom1.18
Dividend Gr. 3/5Y- - Current Ratio0.92 EPS Q/Q- SMA20-8.94% Beta0.74 Target Price11.15
Payout- Debt/Eq- Sales Q/Q- SMA50-11.81% Rel Volume0.32 Prev Close2.98
Employees119 LT Debt/Eq- EarningsMar 26 AMC SMA2008.39% Avg Volume22.38K Price3.01
IPOJul 10, 2020 Option/ShortNo / Yes EPS/Sales Surpr.-188.15% 64.54% Trades Volume7,112 Change1.01%
Date Action Analyst Rating Change Price Target Change
Feb-21-25Initiated TD Cowen Buy $10
Nov-12-24Initiated UBS Neutral $3
Oct-27-23Initiated Canaccord Genuity Buy $12
May-31-23Initiated ROTH MKM Buy $11
May-19-23Upgrade Societe Generale Sell → Buy
Mar-17-23Initiated Stifel Buy $27
Nov-15-22Downgrade Societe Generale Buy → Sell
Mar-08-21Downgrade Societe Generale Buy → Sell
Aug-05-20Initiated ROTH Capital Buy
Aug-04-20Initiated Stifel Buy $18
Jul-02-25 04:00PM
Jun-24-25 03:51PM
Jun-10-25 04:00PM
Jun-03-25 12:00PM
May-27-25 04:00PM
02:30AM Loading…
May-23-25 02:30AM
02:00AM
May-22-25 08:00AM
May-05-25 02:30AM
Apr-30-25 04:00PM
04:00PM
Apr-24-25 04:01PM
Apr-15-25 04:00PM
Apr-04-25 09:40AM
Apr-01-25 05:00PM
10:50AM Loading…
Mar-27-25 10:50AM
Mar-26-25 04:00PM
Mar-19-25 04:00PM
Feb-26-25 04:00PM
Feb-20-25 04:00PM
Feb-10-25 04:00PM
Jan-29-25 04:00PM
Jan-24-25 04:00PM
Jan-22-25 04:00PM
Dec-17-24 04:00PM
Dec-16-24 02:30AM
Dec-12-24 04:00PM
Nov-21-24 04:00PM
Nov-20-24 04:00PM
04:00PM
04:00PM Loading…
Nov-15-24 04:00PM
Oct-30-24 04:00PM
Oct-21-24 08:30AM
Oct-14-24 01:45PM
02:35AM
02:30AM
Sep-25-24 04:00PM
Jul-31-24 04:00PM
Jul-25-24 04:00PM
Jul-19-24 11:30AM
Jul-18-24 02:30AM
Jul-05-24 04:00PM
Jun-21-24 04:05PM
04:00PM
Jun-18-24 09:35AM
May-30-24 02:30AM
02:30AM
May-22-24 04:00PM
May-21-24 04:00PM
May-16-24 04:00PM
May-13-24 04:08PM
02:30AM
Apr-03-24 04:00PM
Apr-01-24 02:17PM
Mar-28-24 03:00AM
Mar-27-24 04:00PM
Mar-22-24 04:00PM
Mar-18-24 04:00PM
Mar-13-24 04:00PM
Mar-07-24 04:00PM
Feb-16-24 05:46AM
Feb-15-24 04:35PM
Jan-24-24 04:15PM
Jan-10-24 04:00PM
Dec-20-23 04:00PM
Dec-04-23 04:05PM
Nov-21-23 04:00PM
Nov-06-23 04:00PM
Oct-27-23 10:01AM
Sep-28-23 04:00PM
Sep-20-23 04:00PM
Aug-31-23 01:30AM
Jul-27-23 04:33PM
04:00PM
Jun-24-23 02:00AM
Jun-13-23 05:00PM
Jun-08-23 02:30AM
Jun-07-23 04:00PM
May-26-23 04:00PM
May-25-23 04:00PM
09:50AM
May-16-23 04:00PM
May-04-23 02:31AM
02:30AM
Apr-09-23 07:34PM
Mar-30-23 08:19AM
Mar-29-23 04:00PM
Mar-23-23 05:00PM
Feb-14-23 05:00PM
04:00PM
Jan-30-23 04:00PM
Jan-26-23 02:00AM
Jan-04-23 04:00PM
Jan-03-23 02:35AM
02:30AM
Dec-12-22 02:30AM
Nov-28-22 04:00PM
Nov-21-22 04:00PM
Nov-10-22 04:00PM
Oct-31-22 07:58AM
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frederic Cren on October 27, 2011 and is headquartered in Daix, France.